Lv Wei, Liu Yijiao, Li Shengnan, Ren Kewei, Fang Hufeng, Chen Hua, Xin Hongliang
Department of Pharmacy, The Jiangyin Clinical College of Xuzhou Medical University, Wuxi, Jiangsu 214499, China.
Department of Oncology, The Jiangyin Clinical College of Xuzhou Medical University, Wuxi, Jiangsu 214499, China.
Chin Med J (Engl). 2025 Aug 20;138(16):1945-1960. doi: 10.1097/CM9.0000000000003685. Epub 2025 Jul 4.
Ischemic stroke (IS) ranks as a leading cause of death and disability globally. The blood-brain barrier (BBB) poses significant challenges for effective drug delivery to brain tissues. Recent decades have seen the development of targeted nanomedicine and biomimetic technologies, sparking substantial interest in biomimetic drug delivery systems for treating IS. These systems are devised by utilizing or replicating natural cells and their derivatives, offering promising new pathways for detection and transport across the BBB. Their multifunctionality and high biocompatibility make them effective treatment options for IS. In addition, the incorporation of engineering techniques has provided these biomimetic drug delivery systems with active targeting capabilities, enhancing the accumulation of therapeutic agents in ischemic tissues and specific cell types. This improvement boosts drug transport and therapeutic efficacy. However, it is crucial to thoroughly understand the advantages and limitations of various engineering strategies employed in constructing biomimetic delivery systems. Selecting appropriate construction methods based on the characteristics of the disease is vital to achieving optimal treatment outcomes. This review summarizes recent advancements in three types of engineered biomimetic drug delivery systems, developed from natural cells and their derivatives, for treating IS. It also discusses their effectiveness in application and potential challenges in future clinical translation.
缺血性中风(IS)是全球范围内导致死亡和残疾的主要原因之一。血脑屏障(BBB)对向脑组织有效递送药物构成了重大挑战。近几十年来,靶向纳米医学和仿生技术不断发展,引发了人们对用于治疗IS的仿生药物递送系统的浓厚兴趣。这些系统是通过利用或复制天然细胞及其衍生物设计而成的,为检测和跨越血脑屏障的运输提供了有前景的新途径。它们的多功能性和高生物相容性使其成为治疗IS的有效选择。此外,工程技术的融入为这些仿生药物递送系统赋予了主动靶向能力,增强了治疗剂在缺血组织和特定细胞类型中的积累。这一改进提高了药物运输和治疗效果。然而,全面了解构建仿生递送系统所采用的各种工程策略的优缺点至关重要。根据疾病的特征选择合适的构建方法对于实现最佳治疗效果至关重要。本综述总结了由天然细胞及其衍生物开发的三种工程化仿生药物递送系统在治疗IS方面的最新进展。它还讨论了它们在应用中的有效性以及未来临床转化中可能面临的挑战。